questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Lectines
Galectines
Galectine -3
Galectine -3 : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Galectine -3 : Questions médicales les plus fréquentes",
"headline": "Galectine -3 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Galectine -3 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-17",
"dateModified": "2025-02-11",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Galectine -3"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Galectines",
"url": "https://questionsmedicales.fr/mesh/D037161",
"about": {
"@type": "MedicalCondition",
"name": "Galectines",
"code": {
"@type": "MedicalCode",
"code": "D037161",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.503.307"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Galectine -3",
"alternateName": "Galectin 3",
"code": {
"@type": "MedicalCode",
"code": "D037502",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Çiğdem Yücel",
"url": "https://questionsmedicales.fr/author/%C3%87i%C4%9Fdem%20Y%C3%BCcel",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry, University of Health Science, Ankara City Hospital, Ankara, Turkey."
}
},
{
"@type": "Person",
"name": "Aybeniz Civan Kahve",
"url": "https://questionsmedicales.fr/author/Aybeniz%20Civan%20Kahve",
"affiliation": {
"@type": "Organization",
"name": "Gazi University Faculty of Medicine, Department of Psychiatry, Ankara, Turkey."
}
},
{
"@type": "Person",
"name": "Işık Batuhan Çakmak",
"url": "https://questionsmedicales.fr/author/I%C5%9F%C4%B1k%20Batuhan%20%C3%87akmak",
"affiliation": {
"@type": "Organization",
"name": "Sungurlu State Hospital, Department of Psychiatry, Corum, Turkey."
}
},
{
"@type": "Person",
"name": "Erol Göka",
"url": "https://questionsmedicales.fr/author/Erol%20G%C3%B6ka",
"affiliation": {
"@type": "Organization",
"name": "University of Health Sciences, Ankara City Hospital, Department of Psychiatry, Ankara, Turkey."
}
},
{
"@type": "Person",
"name": "Massiullah Shafaq-Zadah",
"url": "https://questionsmedicales.fr/author/Massiullah%20Shafaq-Zadah",
"affiliation": {
"@type": "Organization",
"name": "Institut Curie, PSL Research University, U1143 INSERM, UMR3666 CNRS, Cellular and Chemical Biology Unit, 75248Paris Cedex 05, France."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Locally injected Mesenchymal Stem Cells optimize angiogenesis by regulating VEGF and CD31 expression in duodenal perforation.",
"datePublished": "2022-09-02",
"url": "https://questionsmedicales.fr/article/36268307",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.amsu.2022.104529"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prediction models for brachytherapy-induced rectal toxicity in patients with locally advanced pelvic cancers: a systematic review.",
"datePublished": "2022-08-31",
"url": "https://questionsmedicales.fr/article/36199943",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.5114/jcb.2022.119427"
}
},
{
"@type": "ScholarlyArticle",
"name": "Phase I/II trial of local interstitial chemotherapy with arsenic trioxide in patients with newly diagnosed glioma.",
"datePublished": "2022-08-30",
"url": "https://questionsmedicales.fr/article/36212657",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fneur.2022.1001829"
}
},
{
"@type": "ScholarlyArticle",
"name": "Technical feasibility of robotic vs. laparoscopic surgery for locally advanced colorectal cancer invading the urinary bladder.",
"datePublished": "2022-08-20",
"url": "https://questionsmedicales.fr/article/35987827",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10151-022-02670-5"
}
},
{
"@type": "ScholarlyArticle",
"name": "Entropy reduction from strong localization - an explanation for enhanced reaction rates of organic synthesis in aqueous micelles.",
"datePublished": "2022-08-18",
"url": "https://questionsmedicales.fr/article/36029596",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jcis.2022.08.105"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Lectines",
"item": "https://questionsmedicales.fr/mesh/D037102"
},
{
"@type": "ListItem",
"position": 5,
"name": "Galectines",
"item": "https://questionsmedicales.fr/mesh/D037161"
},
{
"@type": "ListItem",
"position": 6,
"name": "Galectine -3",
"item": "https://questionsmedicales.fr/mesh/D037502"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Galectine -3 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Galectine -3",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Galectine -3",
"description": "Comment mesurer le taux de galectine-3 ?\nQuels tests sont utilisés pour le diagnostic ?\nLa galectine-3 est-elle un biomarqueur ?\nQuels médecins évaluent la galectine-3 ?\nPeut-on détecter la galectine-3 dans l'urine ?",
"url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Scleroderma,+Localized&page=999#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Galectine -3",
"description": "Quels symptômes sont liés à la galectine-3 ?\nLa galectine-3 cause-t-elle des douleurs ?\nY a-t-il des symptômes cardiaques associés ?\nLa galectine-3 est-elle liée à la fatigue ?\nQuels signes cliniques sont observés ?",
"url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Scleroderma,+Localized&page=999#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Galectine -3",
"description": "Comment prévenir l'augmentation de la galectine-3 ?\nL'exercice physique influence-t-il la galectine-3 ?\nY a-t-il des aliments à éviter ?\nLe stress affecte-t-il la galectine-3 ?\nDes suppléments peuvent-ils aider à la prévention ?",
"url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Scleroderma,+Localized&page=999#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Galectine -3",
"description": "Quels traitements ciblent la galectine-3 ?\nLa galectine-3 peut-elle être traitée par des médicaments ?\nY a-t-il des traitements naturels pour la galectine-3 ?\nLes traitements varient-ils selon la maladie ?\nLa thérapie génique peut-elle cibler la galectine-3 ?",
"url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Scleroderma,+Localized&page=999#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Galectine -3",
"description": "Quelles complications sont liées à la galectine-3 ?\nLa galectine-3 aggrave-t-elle les maladies ?\nY a-t-il des risques de cancer associés ?\nLa galectine-3 influence-t-elle la fibrose ?\nDes complications neurologiques sont-elles possibles ?",
"url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Scleroderma,+Localized&page=999#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Galectine -3",
"description": "Quels facteurs augmentent la galectine-3 ?\nLe tabagisme influence-t-il la galectine-3 ?\nL'âge est-il un facteur de risque ?\nLe stress chronique est-il un facteur de risque ?\nY a-t-il un lien avec les maladies auto-immunes ?",
"url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Scleroderma,+Localized&page=999#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment mesurer le taux de galectine-3 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le taux de galectine-3 se mesure par un test sanguin spécifique."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des examens d'imagerie peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "La galectine-3 est-elle un biomarqueur ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est considérée comme un biomarqueur pour certaines maladies."
}
},
{
"@type": "Question",
"name": "Quels médecins évaluent la galectine-3 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cardiologues et oncologues évaluent souvent la galectine-3."
}
},
{
"@type": "Question",
"name": "Peut-on détecter la galectine-3 dans l'urine ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La galectine-3 est principalement mesurée dans le sang, pas dans l'urine."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à la galectine-3 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est associée à des symptômes d'inflammation et de fibrose."
}
},
{
"@type": "Question",
"name": "La galectine-3 cause-t-elle des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut contribuer à des douleurs liées à des maladies inflammatoires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes cardiaques associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme l'essoufflement peuvent être présents."
}
},
{
"@type": "Question",
"name": "La galectine-3 est-elle liée à la fatigue ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut être associée à la fatigue dans des conditions inflammatoires."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont observés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme l'œdème et la dyspnée peuvent être observés."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'augmentation de la galectine-3 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une alimentation équilibrée, peut aider."
}
},
{
"@type": "Question",
"name": "L'exercice physique influence-t-il la galectine-3 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut réduire les niveaux de galectine-3."
}
},
{
"@type": "Question",
"name": "Y a-t-il des aliments à éviter ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les aliments transformés et riches en sucres peut être bénéfique."
}
},
{
"@type": "Question",
"name": "Le stress affecte-t-il la galectine-3 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut augmenter les niveaux de galectine-3."
}
},
{
"@type": "Question",
"name": "Des suppléments peuvent-ils aider à la prévention ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains suppléments, comme les oméga-3, peuvent être bénéfiques."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent la galectine-3 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs de galectine-3 sont en développement pour diverses maladies."
}
},
{
"@type": "Question",
"name": "La galectine-3 peut-elle être traitée par des médicaments ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments visent à réduire son activité dans le corps."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements naturels pour la galectine-3 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des approches diététiques et des suppléments peuvent aider à la réguler."
}
},
{
"@type": "Question",
"name": "Les traitements varient-ils selon la maladie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements dépendent de la maladie associée à la galectine-3."
}
},
{
"@type": "Question",
"name": "La thérapie génique peut-elle cibler la galectine-3 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches explorent la thérapie génique pour moduler son expression."
}
},
{
"@type": "Question",
"name": "Quelles complications sont liées à la galectine-3 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est liée à des complications cardiovasculaires et pulmonaires."
}
},
{
"@type": "Question",
"name": "La galectine-3 aggrave-t-elle les maladies ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut aggraver des maladies comme l'insuffisance cardiaque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de cancer associés ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de galectine-3 sont associés à un risque accru de cancer."
}
},
{
"@type": "Question",
"name": "La galectine-3 influence-t-elle la fibrose ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle joue un rôle clé dans le développement de la fibrose tissulaire."
}
},
{
"@type": "Question",
"name": "Des complications neurologiques sont-elles possibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent un lien entre galectine-3 et maladies neurodégénératives."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent la galectine-3 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'obésité, le diabète et l'inflammation chronique augmentent la galectine-3."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il la galectine-3 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque pour des niveaux élevés."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les niveaux de galectine-3 augmentent souvent avec l'âge."
}
},
{
"@type": "Question",
"name": "Le stress chronique est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut contribuer à des niveaux élevés de galectine-3."
}
},
{
"@type": "Question",
"name": "Y a-t-il un lien avec les maladies auto-immunes ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les maladies auto-immunes peuvent augmenter les niveaux de galectine-3."
}
}
]
}
]
}
Duodenal perforation is considered as one of gastrointestinal emergency with high morbidity and mortality rate. The MSCs have the ability to improve wound healing by releasing several growth factors a...
MSCs were isolated from rat umbilical cord and injected into duodenal wound site at doses of 1.5x10 [(Putra et al., 2018) 66 cells for T1 group and 3x10 [(Putra et al., 2018) 66 cells for T2 group. Th...
Results showed a significant increase in VEGF and CD31 expression on days 3 and 7 (p < 0,05). The VEGF level was significantly decreased on day 7 compared to day 3....
The administration of MSCs improved the angiogenesis process in duodenal perforation by enhancing VEGF and CD31 expression....
Rectal toxicity remains a major threat to quality of life of patients, who receive brachytherapy to the abdominal pelvic area. Estimating the risk of toxicity development is essential to maximize ther...
To identify relevant studies since 1995, MEDLINE database was searched on August 31, 2021, using terms related to "pelvic cancers", "brachytherapy", "prediction models", and "rectal toxicity". Papers ...
Thirty models (...
Existing models have limited clinical application due to poor quality of methodology. The following key issues should be considered in future studies: 1) Measuring patient-reported outcomes to address...
Glioma is the most common primary brain tumor in adults with poor prognosis. The glioma patients benefit from STUPP strategy, including maximum and safe resection and adjuvant radiotherapy and chemoth...
The arsenic trioxide has the potent therapeutic effect on glioma. However, the safety and efficacy of local interstitial chemotherapy with arsenic trioxide in newly diagnosed glioma patients is unclea...
All patients received partial or complete tumor resection and intraoperative implantation of Ommaya reservoirs followed by standard radiotherapy. Arsenic trioxide with the starting dose 0.3 mg was adm...
No hematological or grade 4 non-hematological toxicity was observed in any patient during arsenic trioxide treatment. The maximum tolerated dose of 1.5 mg of arsenic trioxide was safe and well tolerat...
These results suggest that arsenic trioxide is safe and well tolerated with local delivery into the tumor cavity of the brain, and the dose recommended for a phase II trial is 1.5 mg....
The aim of this study was to determine if robotic surgery can reproduce the technical advantages and oncologic outcomes of laparoscopic surgery for the treatment of locally advanced colorectal cancer ...
We retrospectively reviewed the prospectively maintained data of patients with locally advanced colorectal cancer invading the urinary bladder undergoing robotic or laparoscopic surgery between June 2...
A total of 41 patients (M:F = 32:9; median age: 63 [42-88] years) were analysed; 32 underwent laparoscopic surgery and 9 underwent robotic surgery. There was no statistically significant difference be...
Robotic surgery can reproduce the technical advantages and oncologic outcomes of laparoscopic surgery for the treatment of locally advanced colorectal cancer invading the urinary bladder. However, lar...
The underlying mechanism for increased reaction rates in micellar catalysis-based organic synthesis is a reduced entropy barrier for the reaction. A two-dimensional localization of reactants and catal...
Quantum chemistry, the COSMO-RS implicit solvent model and statistical thermodynamics were employed to predict the stability of a range of reactants, catalysts and intermediates in a series of surfact...
The predicted reaction rates for the proposed mechanism show that the entropy reduction leads to a larger prefactor for the reaction. The resulting reaction rate can be significantly higher than conve...
The task of classification and localization with detecting abnormalities in medical images is considered very challenging. Computer-aided systems have been widely employed to address this issue, and t...
Location information is the primary feature of wireless sensor networks, and it is more critical for Mobile Wireless Sensor Networks (MWSN) to monitor specific targets. How to improve the localization...
Several kinds of stress promote the formation of three-stranded RNA:DNA hybrids called R-loops. Insufficient clearance of these structures promotes genomic instability and DNA damage, which ultimately...
Early detection of non-response to neoadjuvant chemoradiotherapy (nCRT) for locally advanced colorectal cancer (LARC) remains challenging. We aimed to assess whether pretreatment radiotherapy planning...
Patients with LARC who were treated with nCRT were retrospectively enrolled between March 2009 and March 2019. Traditional radiological characteristics were analyzed by visual inspection and radiomic ...
This study enrolled a total of 215 patients, including 151 patients in the training cohort (50 non-responders and 101 responders) and 64 patients in the validation cohort (21 non-responders and 43 res...
Pretreatment CT radiomics achieved satisfying performance in predicting non-response to nCRT and could be helpful to assist in treatment planning for patients with LARC....
The aim of this study was to identify novel milk coagulants to be used in cheesemaking. For this purpose, aqueous extracts from safflower (...